Nuvectis Pharma, Inc. · NASDAQ:NVCT
Nuvectis Pharma — Q3 2026 Earnings Presentation
23 slides from Nuvectis Pharma's earnings presentation, Nov 4, 2026
Slide 1: Nuvectis Pharma, Inc.
NA SD AQ : NV CT Nuvectis Pharma, Inc. Precision Medicine for the Treatment of Complement Related Diseases and Cancer November 2026
Slide 2: Forward Looking Statements
NUVE CTI S PHARM A, INC. Forward Looking Statements This presentation contains "forward-looking statements" within the meaning The outcome of the events described in these forward-looking statements of the U.S. federal securities laws, which statements are subject to are subject to inherent uncertai
Slide 3: About Nuvectis
CO RPO RATE O VERV IE W About Nuvectis Management team with track record of success APPR OVED PRO DU CT APPROVED PRO DUCT APPROVED PRO DUCT Global regulatory approvals (FDA, EMA and PMDA) in renal, anemia and oncology indications Jelmyto® (mitomycin) M A N A G EM E N T TEA M Ron Bentsur Chairman, Ch
Slide 4: Transformative Licensing Agreement with Haisco in June 2026
CO RPO RATE O VERV IE W Transformative Licensing Agreement with Haisco in June 2026 Well capitalized to execute a broad clinical plan $115M FI N A N C I A L H I G H L IG H T S • Well-positioned to reach key inflection points • Multiple near-term clinical and regulatory catalysts expected Completed $
Slide 5: Ciprocopan (NXP100)
0 1 · CO MP LE ME NT Ciprocopan (NXP100) Once Daily, Oral Factor B Inhibitor for the Treatment of Complement Related Diseases 01 Ciprocopan (NXP100) 02 NXP200 03 NXP900 04 Milestones and News Flow
Slide 6: Ciprocopan (NXP100): Convenient, Once-Daily Oral Factor B Inhibitor
CI PRO CO P AN ( NXP1 00) Ciprocopan (NXP100): Convenient, Once-Daily Oral 01 Clinical and regulatory validation in PNH Factor B Inhibitor • China approval in treatment-naïve patients • Previously treated PNH indication approval pending in China Potential best-in-class complement Factor B inhibitor
Slide 7: Ciprocopan/NXP100: Factor B Becoming a Paramount Target in PNH
CI PRO CO P AN ( NXP1 00) · PNH Ciprocopan/NXP100: Factor B Becoming a PN H M A R K ET Paramount Target in PNH Treatment is gradually shifting toward Factor B inhibition (oral, better efficacy) ~$4.7B ~$7.4B Today, projected to 2030 (a) 1ST G EN ER A T IO N 2N D G EN ER A TI O N N E XT G EN E R AT I
Slide 8: Ciprocopan's First Global Approval (China): Treatment Naive PNH
CI PRO CO P AN ( NXP1 00) · PNH Ciprocopan’s First Global Approval (China): Treatment Naive PNH Demonstrated superiority vs Soliris (eculizumab, injectable C5 inhibitor class) TO P LI NE PHASE 3 RES ULTS Ciprocopan* 200mg QD (N=37) Eculizumab (N=36) ST UD Y DE SI GN Randomized 1:1 · Treatment Period
Slide 9: Ciprocopan's 2nd Marketing Application in China
CI PRO CO P AN ( NXP1 00) · PNH ST UDY DESI G N Ciprocopan’s 2nd Marketing Application in Ciprocopan* 200 mg QD · Treatment Period 24 weeks China Primary endpoint - Proportion of participants achieving Previously-treated PNH - Patients with persistent anemia despite treatment with hemoglobin levels≥
Slide 10: Ciprocopan (NXP100) Has Best In Class Potential in IgAN
CI PRO CO P AN ( NXP1 00) · I G AN Reduction in 24h-UPCR* relative to baseline vs. placebo Ciprocopan (NXP100) Week 4 Week 12 Week 24 Has Best In Class Potential in IgAN Phase 2 data efficacy positions ciprocopan -33% potentially in line with APRIL/BAFF inhibitors (all injectables) -45.3% (Primary E
Slide 11: Complement Factor B FDA Approvals and Ongoing Clinical Trials
CI PRO CO P AN ( NXP1 00) Complement Factor B FDA Approvals and Ongoing Clinical Trials Est. US addressable patient Fabhalta approvals and ongoing . Indication population clinical trials Ciprocopan (Status) PNH - Naive Treatment naïve (China) ~5,500 PNH - Experienced Approval pending (China) APPROVA
Slide 12: NXP200
0 2 · ON CO LO GY NXP200 A Paradox-Breaker BRAF Inhibitor for the Treatment of Cancer 01 Ciprocopan (NXP100) 02 NXP200 03 NXP900 04 Milestones and News Flow
Slide 13: BRAF in Cancer
NXP2 00 BRAF in Cancer Cancers with high Papillary Cholangio- prevalence of BRAF Melanoma Colorectal NSCLC CNS mutations Thyroid carcinoma FI R ST G EN ER A TI O N W H Y I T M A TTE R S FO R THE BRA F M UTATI O N B R A F I N H I B I TO R S NXP200 mutations in codon 600 (most commonly V600E), Class 1
Slide 14: NXP200: A Large Next-Generation BRAF Opportunity
NXP2 00 NXP200: A Large Next-Generation BRAF Opportunity Oral, brain-penetrant, paradox-breaker BRAF inhibitor with potential best-in-class properties M ARKET T O DAY M A R K ET P O TEN T IA L $5BN First-generation BRAF inhibitors $12BN With next-generation paradox-breaker inhibitors* BENCHM AR K DE
Slide 15: NXP200: Paradox Breaker BRAFi
NXP2 00 · F REE BASE ( O LD) FO RM UL ATI O N NXP200: Paradox Breaker BRAFi Clinical proof of concept: Single agent responses in heavily pre-treated patients Preliminary Efficacy Data – Phase I dose escalation Treatment with NXP200 resulted in ORR of 37% (7/19) (all pts. Previously treated with recu
Slide 16: NXP200: ESMO 2026 Recurrent/Progressive Glioma Clinical Data Update
NXP2 00 · G LI O M A NXP200: ESMO 2026 Recurrent/Progressive Glioma Clinical Data Update Phase 1b: Durable Single Agent Responses (Including CRs) in BRAF V600-mutate recurrent or progressive gliomas NXP200: Anti-tumor Activity: Early Evidence by RANO 2.0 Single Agent Efficacy Data LGG HGG * Prior BR
Slide 17: NXP200: New Salt Form
NXP2 00 · N EW S ALT FO R M NXP200: New Salt Form Clinical proof of concept (pilot study): single agent responses in heavily pre-treated patients New Salt form enhances NXP200 systemic exposure Preliminary Single Agent Efficacy Data (all pts. previously treated with recurrent metastatic disease) Geo
Slide 18: NXP900
0 3 · ON CO LO GY NXP900 A SRC/YES1 Kinase Inhibitor for the treatment of Cancer 01 Ciprocopan (NXP100) 02 NXP200 03 NXP900 04 Milestones and News Flow
Slide 19: NXP900 Phase 1b Ongoing
NXP9 00 NXP900 Phase 1b Ongoing Highly selective, unique mechanism of action: Complete shut-down of the YES1/SRC pathways by inhibiting the catalytic and scaffolding properties STUDY INDICATIO N CO MBINATION PATI ENTS STATUS EGFR mutated, previous response to #1 NSCLC osimertinib combination osimert
Slide 20: NXP900 Combination With RAS Inhibitors
NXP9 00 NXP900 Combination With RAS Inhibitors SRC activation is involved in multiple pathways leading to acquired resistance to Ras inhibition** SRC, YES1 and YAP1 activation have been 1 validated preclinically as drivers of resistance to RAS inhibitors. NXP900 inhibits at low nanomolar concentrati
Slide 21: Milestones and News Flow
04 Milestones and News Flow 01 Ciprocopan (NXP100) 02 NXP200 03 NXP900 04 Milestones and News Flow
Slide 22: Expected Near-Term News Flow & Catalysts
M I LEST O NES AND NEW S FL O W Expected Near-Term News Flow & Catalysts PROG RAM July 2026 H2 2026 Q4 2026 Dec 2026 H1 2027 Approval (China) — US IND submission Approval (China) — PNH Phase 3 data IgAN Pivotal Phase 3 treatment-naïve PNH previously-treated PNH (China) presentations Topline (China)
Slide 23: Thank You
Ciprocopan (NXP100) NXP200 NXP900 Factor B Inhibitor Paradox-breaker BRAF Inhibitor SRC/YES1 Kinase Inhibitor Thank You Precision Medicine for the Treatment of Complement Related N A SD A Q : N V C T Diseases and Cancer nuvectis.com